These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 31341534)

  • 1. MYC Expression and Metabolic Redox Changes in Cancer Cells: A Synergy Able to Induce Chemoresistance.
    Marengo B; Garbarino O; Speciale A; Monteleone L; Traverso N; Domenicotti C
    Oxid Med Cell Longev; 2019; 2019():7346492. PubMed ID: 31341534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitor of differentiation 1 transcription factor promotes metabolic reprogramming in hepatocellular carcinoma cells.
    Sharma BK; Kolhe R; Black SM; Keller JR; Mivechi NF; Satyanarayana A
    FASEB J; 2016 Jan; 30(1):262-75. PubMed ID: 26330493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic regulation of tumor metabolic reprogramming.
    Tarrado-Castellarnau M; de Atauri P; Cascante M
    Oncotarget; 2016 Sep; 7(38):62726-62753. PubMed ID: 28040803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance.
    Fatma H; Maurya SK; Siddique HR
    Semin Cancer Biol; 2022 Aug; 83():166-176. PubMed ID: 33220458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating β-catenin/c-Myc signaling in human hepatocellular carcinoma.
    Liu R; Li Y; Tian L; Shi H; Wang J; Liang Y; Sun B; Wang S; Zhou M; Wu L; Nie J; Lin B; Tang S; Zhang Y; Wang G; Zhang C; Han J; Xu B; Liu L; Gong K; Zheng T
    Cancer Lett; 2019 Feb; 443():34-46. PubMed ID: 30503555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic targeting of oncogene MYC by selective activation of the proton-coupled monocarboxylate family of transporters.
    Gan L; Xiu R; Ren P; Yue M; Su H; Guo G; Xiao D; Yu J; Jiang H; Liu H; Hu G; Qing G
    Oncogene; 2016 Jun; 35(23):3037-48. PubMed ID: 26434591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of MYC in regulation of tumor cell metabolism.
    Wahlström T; Henriksson MA
    Biochim Biophys Acta; 2015 May; 1849(5):563-9. PubMed ID: 25038584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PKM2 depletion induces the compensation of glutaminolysis through β-catenin/c-Myc pathway in tumor cells.
    Wu H; Li Z; Yang P; Zhang L; Fan Y; Li Z
    Cell Signal; 2014 Nov; 26(11):2397-405. PubMed ID: 25041845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYC and tumor metabolism: chicken and egg.
    Dejure FR; Eilers M
    EMBO J; 2017 Dec; 36(23):3409-3420. PubMed ID: 29127156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation.
    Wang R; Dillon CP; Shi LZ; Milasta S; Carter R; Finkelstein D; McCormick LL; Fitzgerald P; Chi H; Munger J; Green DR
    Immunity; 2011 Dec; 35(6):871-82. PubMed ID: 22195744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The molecular determinants of de novo nucleotide biosynthesis in cancer cells.
    Tong X; Zhao F; Thompson CB
    Curr Opin Genet Dev; 2009 Feb; 19(1):32-7. PubMed ID: 19201187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A long noncoding RNA connects c-Myc to tumor metabolism.
    Hung CL; Wang LY; Yu YL; Chen HW; Srivastava S; Petrovics G; Kung HJ
    Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18697-702. PubMed ID: 25512540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic targeting of Myc-reprogrammed cancer cell metabolism.
    Dang CV
    Cold Spring Harb Symp Quant Biol; 2011; 76():369-74. PubMed ID: 21960526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The interplay between MYC and HIF in the Warburg effect.
    Dang CV
    Ernst Schering Found Symp Proc; 2007; (4):35-53. PubMed ID: 18811052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC, PARP1, and chemoresistance: BIN there, done that?
    Ganesan S
    Sci Signal; 2011 Mar; 4(166):pe15. PubMed ID: 21447796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells.
    Chen JQ; Russo J
    Biochim Biophys Acta; 2012 Dec; 1826(2):370-84. PubMed ID: 22750268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attacking c-Myc: targeted and combined therapies for cancer.
    Huang H; Weng H; Zhou H; Qu L
    Curr Pharm Des; 2014; 20(42):6543-54. PubMed ID: 25341931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The inhibition of c-MYC transcription factor modulates the expression of glycolytic and glutaminolytic enzymes in FaDu hypopharyngeal carcinoma cells.
    Kleszcz R; Paluszczak J; Krajka-Kuźniak V; Baer-Dubowska W
    Adv Clin Exp Med; 2018 Jun; 27(6):735-742. PubMed ID: 29790697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interplay between sirtuins, MYC and hypoxia-inducible factor in cancer-associated metabolic reprogramming.
    Zwaans BM; Lombard DB
    Dis Model Mech; 2014 Sep; 7(9):1023-32. PubMed ID: 25085992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYC and metabolism on the path to cancer.
    Hsieh AL; Walton ZE; Altman BJ; Stine ZE; Dang CV
    Semin Cell Dev Biol; 2015 Jul; 43():11-21. PubMed ID: 26277543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.